Oren Hershkovitz
Algemeen Directeur bij ENLIVEX THERAPEUTICS LTD.
Vermogen: 36 968 $ op 30-04-2024
Actieve functies van Oren Hershkovitz
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ENLIVEX THERAPEUTICS LTD. | Algemeen Directeur | 16-11-2019 | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Directeur/Bestuurslid | 01-09-2016 | - |
Loopbaan van Oren Hershkovitz
Opleiding van Oren Hershkovitz
Ben-Gurion University of the Negev | Doctorate Degree |
Statistieken
Internationaal
Israël | 4 |
Operationeel
Chief Executive Officer | 1 |
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
- Beurs
- Insiders
- Oren Hershkovitz
- Ervaring